Skip to main content
. Author manuscript; available in PMC: 2021 Feb 10.
Published in final edited form as: Br J Haematol. 2019 Nov 4;188(3):e11–e15. doi: 10.1111/bjh.16268

Table 1. Patient demographics and baseline characteristics of FLAVIDA and FLA-IDA control patients.

Baseline characteristics FLAVIDA (n=13) FLA-IDA control (n=81) P
Age (years)
    Median (range)
49 (18-62)
52 (22-72)		 0·39
Sex n (%)
    Male
    Female
8 (61·5)
5 (38·5)
45 (55·6)
36 (44·4)		 0·69
Type of AML n (%)
    De novo
    Secondary
    Missing
8 (61·5)
5 (38·5)
-
61 (75·3)
19 (23·5)
1 (1·2)		 0·49
FAB Subtype n (%)
    M0
    M1
    M2
    M4
    M4eo
    M5
    M6
    M7
    Missing
-
4 (30·8)
3 (23·1)
3 (23·1)
-
3 (23·1)
-
-
-
11 (13·6)
11 (13·6)
12 (14·8)
12 (14·8)
1 (1·2)
16 (19·8)
-
1 (1·2)
17 (21)		 0·27
ELN classification 2017 n (%)
    Favourable
    Intermediate
    Adverse
    Missing
2 (15·4)
7 (53·8)
4 (30·8)
-
17 (21)
35 (43·2)
18 (22·2)
11 (13·6)		 0·46
Complex karyotype n (%)
    Yes
    No
    Missing
2 (15·4)
11(84·6)
-
7 (8.6)
66 (81.5)
8 (9.9)		 0.41
Treatment lines before FLAV/IDA
    Median (range)
1 (1-5)
1 (1-4)		 0·42
WBC at start of salvage (x109/l)
    Median (range)
    Missing
3·0 (0·5-77)
-
2·8 (0·1-117·3)
14		 0·45
Haemoglobin at start salvage (g/dl)
    Median (range)
    Missing
9·3 (6·5-11·6)
-
9·3 (6·6-14·9)
14		 0·65
Platelet count at start of salvage (x109/l)
    Median (range)
    Missing
47 (5-202)
-
51 (5-731)
14		 0·58
Blasts in BM at start of salvage (%)
    Median (range)
    Missing
70 (12-100)
1
50 (10-100)
42		 0·06
Blasts in PB at start of salvage (%)
    Median (range)
    Missing
7 (0-98)
-
15 (10-90)
38		 0·68
FLT3 status n (%)
    Wildtype
    Mutated
    Missing
9 (69·2)
4 (30·8)
-
49 (60·5)
13 (16)
19 (23·5)		 0·87
NPM1 status n (%)
    Wildtype
    Mutated
    Missing
10 (76·9)
3 (23·1)
-
43 (53)
19 (23·5)
19 (23·5)		 0·27
AlloHCT before FLAV/IDA n (%)
    Yes
    No
6 (46·2)
7 (53·8)
22 (27·2)
59 (72·8)		 0·17
AlloHCT after FLAV/IDA n (%)
    First alloHCT
    Second alloHCT
    No
    Missing
7 (53·8)
2 (15·4)
4 (30·8)
-
49 (60·5)
6 (7·4)
25 (30·9)
1 (1·2)		 1·0
Use of G-CSF
    Concomitant to chemotherapy
    After chemotherapy
    No use
    Missing
-
8 (61·5)
5 (38·5)
-
50 (61·7)
6 (7·4)
18 (22·2)
7 (8·6)		 -

Dates are n (%) or median (range) unless otherwise noted. ECOG=Eastern Cooperative Oncology Group; WBC=white-cell count; BM=bone marrow; PB=peripheral blood; alloHCT=allogeneic hematopoietic cell transplantation.